Skip to main content

Search
Profile

Margaret Rosenfeld, MD, MPH

|
Margaret Rosenfeld, MD, MPH

Pulmonary and Sleep Medicine, Cystic Fibrosis Research

On staff since May 1995

Children's Title: Director, Clinical Research Scholars Program; Associate Director, Center for Clinical and Translational Research

Academic Title: Professor, Department of Pediatrics

Research Center: Center for Clinical and Translational Research

Making a Difference

  • Making the Smartphone Smarter

    A novel mobile phone app being developed at Seattle Children’s and the University of Washington may transform care for patients with chronic lung diseases.... cont.

Recommendations

EllisaChehalis, WA03.21.11
We first saw Dr. Rosenfeld when our child was very young, around 4 months old. We were seeing her to determine if our child had PCD. She was very caring, thourough, and was willing to sit and answer all our questions as long as we needed. She has continued caring for our child, who is now 2. We are so greatful to have such a knowledgable Doctor taking care of our child and helping us prevent future health problems and research this rare pulmonary disorder. We highly recommend her. Ellisa Alderson
Recommend Dr. Margaret Rosenfeld

Overview

Board Certification(s)
Pediatric Pulmonology
Medical/Professional School
Harvard Medical School, Boston
University of Washington, Seattle
Clinical Interests

Early lung disease in cystic fibrosis, Cystic fibrosis epidemiology

Research Description

Clinical and epidemiologic research in cystic fibrosis (CF), emphasizing early CF lung disease. Development of outcome measures for clinical trials in young CF patients, including infant and preschool lung function tests.

Research Focus Area

Therapeutic Trials

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
Finalist, UW School of Medicine Mentoring Award 2013
Finalist, UW School of Medicine Mentoring Award 2010
Physician Scientist Fellowship AwardGlaxo Corporation 1993
Leroy Matthews Physician Scientist AwardCystic Fibrosis Foundation 1992 - 1998

Publications

The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF Registry.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2013 Dec 12
Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia.
Annals of the American Thoracic Society , 2013 Dec: 10(6)574-81
Association of lung function, chest radiographs and clinical features in infants with cystic fibrosis.
The European respiratory journal , 2013 Dec: 42(6)1545-52
Small airway involvement in cystic fibrosis lung disease: routine spirometry as an early and sensitive marker.
Pediatric pulmonology , 2013 Nov: 48(11)1081-8
Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia.
American journal of human genetics , 2013 Oct 3: 93(4)672-86
Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.
The Journal of pediatrics , 2013 Oct: 163(4)1152-7.e2
Early childhood wheezing is associated with lower lung function in cystic fibrosis.
Pediatric pulmonology , 2013 Oct 1
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
Pediatric pulmonology , 2013 Oct: 48(10)943-53
Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials.
Contemporary clinical trials , 2013 Sep: 36(1)99-105
Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease?
The European respiratory journal , 2013 Sep: 42(3)844-57
Opportunities and pitfalls of registry data for clinical research.
Paediatric respiratory reviews , 2013 Sep: 14(3)141-5
Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline.
American journal of respiratory and critical care medicine , 2013 Aug 15: 188(4)456-60
ZMYND10 is mutated in primary ciliary dyskinesia and interacts with LRRC6.
American journal of human genetics , 2013 Aug 8: 93(2)336-45
ARMC4 mutations cause primary ciliary dyskinesia with randomization of left/right body asymmetry.
American journal of human genetics , 2013 Aug 8: 93(2)357-67
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
Pediatric pulmonology , July 2013
Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age.
Thorax , July 2013: 68(7)643-51
Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?
The European respiratory journal , 2013 Aug: 42(2)527-38
Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials.
Contemporary clinical trials , June 2013: 36(1)99-105
Survey of clinical infant lung function testing practices.
Pediatric pulmonology , June 2013
Lung Clearance Index as an Outcome Measure for Clinical Trials in Young Children with Cystic Fibrosis: A Pilot Study using Inhaled Hypertonic Saline.
American journal of respiratory and critical care medicine , June 2013
Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age.
Thorax , 2013 Jul: 68(7)643-51
Survey of clinical infant lung function testing practices.
Pediatric pulmonology , 2013 Jun 13
Association of lung function, Chest radiographs and clinical features in infants with cystic fibrosis.
The European respiratory journal , May 2013
Opportunities and pitfalls of registry data for clinical research.
Paediatric respiratory reviews , May 2013
An official American Thoracic Society workshop report: optimal lung function tests for monitoring cystic fibrosis, bronchopulmonary dysplasia, and recurrent wheezing in children less than 6 years of age.
Annals of the American Thoracic Society , April 2013: 10(2)S1-S11
Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.
Journal of aerosol medicine and pulmonary drug delivery , April 2013: 26(2)69-75
Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?
The European respiratory journal , March 2013
Mutations in CCDC39 and CCDC40 are the major cause of primary ciliary dyskinesia with axonemal disorganization and absent inner dynein arms.
Human mutation , March 2013: 34(3)462-72
An official American Thoracic Society workshop report: optimal lung function tests for monitoring cystic fibrosis, bronchopulmonary dysplasia, and recurrent wheezing in children less than 6 years of age.
Annals of the American Thoracic Society , 2013 Apr: 10(2)S1-S11
Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.
Journal of aerosol medicine and pulmonary drug delivery , 2013 Apr: 26(2)69-75
Small airway involvement in cystic fibrosis lung disease: Routine spirometry as an early and sensitive marker.
Pediatric pulmonology , Feb. 2013
Mutations in CCDC39 and CCDC40 are the major cause of primary ciliary dyskinesia with axonemal disorganization and absent inner dynein arms.
Human mutation , 2013 Mar: 34(3)462-72
Exome sequencing identifies mutations in CCDC114 as a cause of primary ciliary dyskinesia.
American journal of human genetics , Jan. 2013: 92(1)99-106
Lung function from infancy to preschool in a cohort of children with cystic fibrosis.
The European respiratory journal , Jan. 2013: 41(1)60-6
Reference equations
Diagnostic Techniques for the Pediatric Pulmonologist , 2013
Exome sequencing identifies mutations in CCDC114 as a cause of primary ciliary dyskinesia.
American journal of human genetics , 2013 Jan 10: 92(1)99-106
Chest computed tomography; a validated surrogate endpoint of cystic fibrosis lung disease?
The European respiratory journal , Dec. 2012
Lung function from infancy to preschool in a cohort of children with cystic fibrosis.
The European respiratory journal , 2013 Jan: 41(1)60-6
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , Sept. 2012: 11(5)446-53
Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , Sept. 2012: 11(5)456-7
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , Aug. 2012
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 Sep: 11(5)446-53
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 Aug 31
Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Nature genetics , July 2012: 44(8)886-9
Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.
JAMA : the journal of the American Medical Association , June 2012: 307(21)2269-77
Revision surgeries are associated with significant increased risk of subsequent cerebrospinal fluid shunt infection.
The Pediatric infectious disease journal , June 2012: 31(6)551-6
Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.
JAMA : the journal of the American Medical Association , 2012 Jun 6: 307(21)2269-77
Revision surgeries are associated with significant increased risk of subsequent cerebrospinal fluid shunt infection.
The Pediatric infectious disease journal , 2012 Jun: 31(6)551-6
Analysis of the associations between lung function and clinical features in preschool children with cystic fibrosis.
Pediatric pulmonology , 2012 Jun: 47(6)574-81
Lung function distinguishes preschool children with CF from healthy controls in a multi-center setting.
Pediatric pulmonology , 2012 Jun: 47(6)597-605
Mutations of DNAH11 in patients with primary ciliary dyskinesia with normal ciliary ultrastructure.
Thorax , 2012 May: 67(5)433-41
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatric pulmonology , Feb. 2012: 47(2)125-34
Association of intraventricular hemorrhage secondary to prematurity with cerebrospinal fluid shunt surgery in the first year following initial shunt placement
J Neurosurg Pediatr. , Jan. 2012: 54-63
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatric pulmonology , 2012 Feb: 47(2)125-34
Mutations of DNAH11 in patients with primary ciliary dyskinesia with normal ciliary ultrastructure.
Thorax , Dec. 2011
Analysis of the associations between lung function and clinical features in preschool children with cystic fibrosis.
Pediatric pulmonology , Nov. 2011
Lung function distinguishes preschool children with CF from healthy controls in a multi-center setting.
Pediatric pulmonology , Nov. 2011
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Archives of pediatrics & adolescent medicine , Sept. 2011: 847-56
Treatment and microbiology of repeated cerebrospinal fluid shunt infections in children.
The Pediatric infectious disease journal , Sept. 2011: 731-5
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatric pulmonology , Aug. 2011
Emergence of oseltamivir-resistant pandemic H1N1 in an immunocompetent child with severe status asthmaticus.
The Journal of asthma : official journal of the Association for the Care of Asthma , Aug. 2011: 572-5
Bronchiectasis and pulmonary exacerbations in children and young adults with cystic fibrosis.
Chest , July 2011: 178-85
Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety.
Pediatric pulmonology , July 2011: 666-71
Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.
Pediatric pulmonology , April 2011: 393-400
Diagnostic yield of nasal scrape biopsies in primary ciliary dyskinesia: A multicenter experience.
Pediatric pulmonology , Jan. 2011
Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints.
American journal of respiratory and critical care medicine , Dec. 2010: 1387-97
Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
Pediatric pulmonology , Sept. 2010: 934-44
Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
American journal of respiratory and critical care medicine , Sept. 2010: 627-32
Therapeutic bilateral lung lavage in a child with pulmonary alveolar proteinosis.
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies , May 2010: e28-31
Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
Pediatric pulmonology , Feb. 2010: 107-17
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Pediatric pulmonology , Feb. 2010: 127-34
Cystic Fibrosis" and "Bronchiectasis
The Netter Collection of Medical Illustrations, 2nd Edition: The Respiratory System , 2010
Pulmonary Exacerbations
Lung Biology in Health and Disease: Cystic Fibrosis , 2010
Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.
The Journal of pediatrics , Dec. 2009: S73-93
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Contemporary clinical trials , May 2009: 256-68
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
The Journal of pediatrics , Feb. 2009: 183-8
Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations.
Pediatric pulmonology , Nov. 2008: 1142-6
Cystic Fibrosis: Respiratory Manifestations
In Pediatric Respiratory Diseases , 2008
Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes.
Genetics in medicine : official journal of the American College of Medical Genetics , Oct. 2007: 695-704
Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
Pediatric pulmonology , Sept. 2007: 751-6
Endpoints for clinical trials in young children with cystic fibrosis.
Proceedings of the American Thoracic Society , Aug. 2007: 418-30
An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all.
Proceedings of the American Thoracic Society , Aug. 2007: 299-301
Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report.
Pediatrics , Feb. 2007: e495-518
Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis.
The Journal of pediatrics , Sept. 2006: 362-6
Cystic fibrosis pulmonary exacerbations.
The Journal of pediatrics , Feb. 2006: 259-64
Disease-specific reference equations for lung function in patients with cystic fibrosis.
American journal of respiratory and critical care medicine , Oct. 2005: 885-91
Overview of published evidence on outcomes with early diagnosis from large US observational studies.
The Journal of pediatrics , Sept. 2005: S11-4
The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study.
The Journal of pediatrics , Aug. 2005: 233-8
Respiratory Mechanics
Pediatric Pulmonary Function Testing , 2005: 3320-33
Update on cystic fibrosis epidemiology.
Current opinion in pulmonary medicine , Nov. 2004: 510-4
Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs.
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control , Oct. 2004: 1-36
Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management.
Current opinion in pulmonary medicine , Nov. 2003: 492-7
Improved survival among young patients with cystic fibrosis.
The Journal of pediatrics , June 2003: 631-6
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
American journal of respiratory and critical care medicine , March 2003: 841-9
Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
Chest , Jan. 2003: 28-36
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
American journal of respiratory and critical care medicine , Dec. 2002: 1550-5
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
Pediatric pulmonology , Aug. 2002: 91-100
Respiratory Mechanics. In Pediatric Pulmonary Function Testing
Respiratory System: Pediatrics. In Cystic Fibrosis , 2000: . 204-218

Presentations

Presentations TitleEventLocationDate
Survey of clinical infant lung function testing practices.International Symposium on Respiratory DiseaseShanghai, ChinaNov. 9, 2013
Early CF Lung Disease: Diagnosis, Treatment and PreventionDuke University School of MedicineNov. 28, 2012
Pulmonary Exacerbation as a Clinical Trial Endpoint: The Pros and ConsNorth American CF ConferenceOrlando, FLOct. 2012
Designing Investigator Initiated TrialsPresentation In symposium "Multidisciplinary Approach to Investigator-initiated Trials," North American CF Conference Orlando, FLOct. 2012
Pulmonary and Nutritional Consequences of CF in the First 6 Years of Lifepresentation in symposium "After the Newborn Screen: What to Do Next?" North American CF ConferenceOrlando, FLOct. 2012
What lung function test is best for managing young children with CFtalk in session "Is it time to bring pre-school lung function testing to the clinic? Update from the ATS/ERS Task Force" European Respiratory Society CongressVienna, AustriaSept. 2012
Writing Your First GrantITHS career development series, University of WashingtonSeattle, WAOct. 30, 2009
Successful Transition to an Academic Careerhalf-day SCH Fellows’ College workshopunknownOct. 28, 2009
Risk factors for early age at acquisition of Pseudomonas aeruginosaNorth American Cystic Fibrosis ConferenceMinneapolis, MNOct. 17, 2009
Newborn screeningNorth American Cystic Fibrosis ConferenceMinneapolis, MNOct. 17, 2009
Pulmonary Exacerbations: How do we define themSymposium presentation, North American Cystic Fibrosis ConferenceMinneapolis, MNOct. 16, 2009
Comparison of published pulmonary exacerbation definitionsCystic Fibrosis Foundation Workshop on Pulmonary ExacerbationsBethesda, MDSept. 9, 2009
Guidelines for Care of theGuidelines for Care of the Infant with CF Infant with CFCystic Fibrosis annual Northwest regional conference, Center for Urban HorticultureunknownJuly 24, 2009
Risk factors for early Pseudomonas acquisitionCystic Fibrosis Epidemiology/Biostatistics Working Group annual meeting, Center for Urban HorticultureunknownJuly 23, 2009
Optimal lung function tests for monitoring cystic fibrosis, bronchopulmonary dysplasia and recurrernt wheezing in children under 6 years of ageAmerican Thoracic Society annual conventionSan Diego, CAMay 12, 2009
unknown33. ITHS Career Development Seminar- Career Development (K Award) SeminarunknownJan. 29, 2009

Research Funding

Grant TitleGrantorAmountAward Date
Validation of a novel cell-phone spirometer in pediatric patients with respiratory diseasesITHS and Coulter Foundation
Novel Home Cough Monitor in Young Children with Cystic Fibrosis: A Pilot and Feasibility StudyCCTR
The EPIC Observational Study: Longitudinal Assessment of Risk Factors and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF (Protocol # EPIC-002)Cystic Fibrosis Foundation
Parent Report of Respiratory and Gastrointestinal Signs in Infants and Young Children with Cystic Fibrosis: A Feasibility studyCCTR
Infant Study of Inhaled SalineNIH and Cystic Fibrosis Foundation
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis and a CFTR Gating Mutation, Age 2to 5Years (VX11-770-108)Vertex
A Phase 3, 2 Arm, Roll-Over Study to Evaluate the Long Term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation (VX11-770-109)Vertex
A Phase 1, Open-Label Study to evaluate the Pharmacokinetics and Safety of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-011)Vertex
Development of an Observer Reported Outcome of Respiratory Signs for Young Children with Cystic FibrosisCCTR
Study of Inhaled Saline in Preschool Children with CF (SHIP): Planning GrantCystic Fibrosis Foundation
Longitudinal Study of Primary Ciliary Dyskinesia: Participants 5 -18 Years of Age (Protocol 5901)NIH
Early Onset and Progression of Primary Ciliary Dyskinesia Lung Disease Prior to 10 Years of Age (RDN #5903)NIH
Testing a Multifactorial Caries Model for Pediatric Patients with Cystic FibrosisSunstar and Cystic Fibrosis Foundation

Primary Office

Seattle Children's
OC.7.720 - Pulmonary
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2174

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options